COMMUNIQUÉS West-GlobeNewswire

Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
02/04/2026
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading global network of electronic health record data Collaboration will expand Regeneron’s world- [...]
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
02/04/2026
HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug [...]
RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
02/04/2026
ALISO VIEJO, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming 25th Annual Needham Virtual Healthcare Conference. Management is scheduled to [...]
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/04/2026
LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on [...]
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
02/04/2026
FOSTER CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of April 1, 2026 [...]
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
02/04/2026
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients [...]
Minerva Announces Leadership Transition
02/04/2026
Jim O’Connor joins as Chief Business Officer and General Counsel BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on [...]
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/04/2026
NEEDHAM, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
02/04/2026
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/04/2026
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 13 newly- [...]
FibroBiologics Announces Closing of $3 Million Public Offering
02/04/2026
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/04/2026
BOSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that [...]
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
02/04/2026
REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today released the following notice: TO: [...]
Get Summer-Season Ready with New Notorious Fitness Training Plans
02/04/2026
Premium Coaching Tiers Maximize Stamina & Physique for Las Vegas Festivals and Day Clubs Las Vegas, Nevada , April 02, 2026 (GLOBE NEWSWIRE) -- As Las Vegas prepares for its world-famous summer entertainment season [...]
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
02/04/2026
MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics [...]
Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid
02/04/2026
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued at [...]
ApolloMD Announces Exclusive Professional Liability Solution with The Doctors Company
02/04/2026
ATLANTA, April 02, 2026 (GLOBE NEWSWIRE) -- ApolloMD, a physician-led practice management organization that provides administrative, operational, and business support services to physician practices nationwide, [...]
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
02/04/2026
2025 financial highlights: Cash and cash equivalents totaled €101.1 million as of December 31, 2025 Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and € [...]
GENFIT : Résultats financiers annuels 2025 et point sur les activités de la Société
02/04/2026
Faits financiers marquants de 2025 : Trésorerie et équivalents de trésorerie s’élevant à 101.1 millions d’euros au 31 décembre 2025 Chiffre d’affaires s’élevant à 65.4 millions d’euros au 31 décembre 2025, dont 43.6 [...]

Pages